- Home
- AMBI vs TNXP Comparison
AMBI vs TNXP Comparison
Compare AMBI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBI
- TNXP
- Stock Information
- Founded
- AMBI 1995
- TNXP 2007
- Country
- AMBI Brazil
- TNXP United States
- Employees
- AMBI N/A
- TNXP N/A
- Industry
- AMBI Environmental Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- AMBI Industrials
- TNXP Health Care
- Exchange
- AMBI Nasdaq
- TNXP Nasdaq
- Market Cap
- AMBI 242.5M
- TNXP 207.5M
- IPO Year
- AMBI N/A
- TNXP N/A
- Fundamental
- Price
- AMBI $4.45
- TNXP $33.33
- Analyst Decision
- AMBI
- TNXP Strong Buy
- Analyst Count
- AMBI 0
- TNXP 2
- Target Price
- AMBI N/A
- TNXP $585.00
- AVG Volume (30 Days)
- AMBI 5.7K
- TNXP 1.1M
- Earning Date
- AMBI 08-12-2014
- TNXP 08-15-2025
- Dividend Yield
- AMBI N/A
- TNXP N/A
- EPS Growth
- AMBI N/A
- TNXP N/A
- EPS
- AMBI N/A
- TNXP N/A
- Revenue
- AMBI $532,477,487.00
- TNXP $10,041,000.00
- Revenue This Year
- AMBI N/A
- TNXP $11.66
- Revenue Next Year
- AMBI N/A
- TNXP $793.18
- P/E Ratio
- AMBI N/A
- TNXP N/A
- Revenue Growth
- AMBI 27.16
- TNXP N/A
- 52 Week Low
- AMBI $3.22
- TNXP $6.76
- 52 Week High
- AMBI $8.20
- TNXP $137.25
- Technical
- Relative Strength Index (RSI)
- AMBI 52.59
- TNXP 52.50
- Support Level
- AMBI $4.58
- TNXP $33.41
- Resistance Level
- AMBI $5.40
- TNXP $37.42
- Average True Range (ATR)
- AMBI 0.26
- TNXP 3.48
- MACD
- AMBI 0.02
- TNXP -1.12
- Stochastic Oscillator
- AMBI 57.79
- TNXP 33.66
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.